Please login to the form below

sumatriptan

This page shows the latest sumatriptan news and features for those working in and with pharma, biotech and healthcare.

Lilly to buy migraine drug developer CoLucid for $960m

Current triptan migraine therapies such as sumatriptan target different 5-HT receptor subtypes, notably 1B and 1D receptors, and stimulating these leads to constriction of blood vessels in the brain as

Latest news

Teva suspends migraine patch on burn reports

Zecuity delivers sumatriptan across the skin by a process known as iontophoresis - in which a mild electric current is applied across the skin and helps to usher active pharmaceutical compounds into ... The AERs are puzzling because iontophoresis has
Teva rolls out first migraine patch in US

The new Zecuity product is a disposable patch system worn for four-hours - on the upper arm or thigh - that delivers the widely-used migraine drug sumatriptan through the skin. ... Sumatriptan is a serotonin 5-HT1 agonist that has been used for years in
Endo's $2.2bn bid for Auxilium Pharma could thwart QLT deal

In the last few months it has also bought NuPathe for $105m - getting hold of migraine patch Zecuity (sumatriptan) - and in June offered $600m for generic player DAVA Pharmaceuticals.
GSK plans to sell off older products

Imitrex (sumatriptan) for migraine, the antidepressant Paxil/Seroxat (paroxetine) and gastrointestinal therapy Zantac (ranitidine) have all been named in dispatches as former blockbuster brands that are now in GSK's 'established
Second darapladib failure disappoints GSK

Sells Treximet to Pernix. Meanwhile, GSK has sold off another brand as it reconfigures its product portfolio, this time handing over US rights to migraine therapy Treximet (sumatriptan/naproxen) to US

More from news
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest Intelligence

Case study: Migraine management

Challenge. Eight years ago, Imigran Recovery (sumatriptan) made the switch from a ‘ POM’ medication to a ‘ P’ licence medicine in a bid to make it more accessible to people who experience ... 80 per cent of coverage mentioned efficacy of
Case study: Migraine management

Challenge. Eight years ago, Imigran Recovery (sumatriptan) made the switch from a ‘ POM’ medication to a ‘ P’ licence medicine in a bid to make it more accessible to people who experience ... 80 per cent of coverage mentioned efficacy of
Deal Watch table for May 2014

Asset / product acquisition. 3. Marketed sumatriptan/naproxen combination. 2013 sales $79m.
Deal Watch table for January 2014

148. NuPathe/ Teva. Company acquisition. Includes key product Zecuity [sumatriptan] for migraine.
Deal Watch table for July 2013

121. ‡ Optinose / Avanir Pharmaceuticals. Licence. Breath Powered intranasal sumatriptan for migraine (p3).